1. Au HJ, Golmohammadi K, Younis T et al (2008) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0034-1
2. Lee SG, Jee YG, Chung HC et al (2008) Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat. doi: 10.1007/s10549-008-0035-0
3. Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163:1637–1641. doi: 10.1001/archinte.163.14.1637
4. Gold MR, Siegel JE, Russell LB et al (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
5. Drummond MF, Sculpher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes. Oxford Medical Publications, New York